CD44 V6、CD44s在胸腹水转移癌中的表达意义

The Expression Significance of CD44V6?CD44s in the Metastatic Carcinoma in Pleural Infusion and Ascites

目的:用免疫组化方法检测粘附分子相关蛋白CD44V6、CD44s在胸腹水转移性癌细胞中的表达情况及临床诊断意义。方法:收集胸腹水标本制成细胞块,结合病史及HE片筛检出间皮细胞反应性增生30例及转移癌57例。免疫组织化学方法采用二步法,一抗用CD44V6、CD44s。结果:CD44V6阳性见于7例(23.33%)反应性增生间皮细胞及21例(36.84%)转移癌细胞;阴性见于23/30(76.67%)例反应性间皮细胞及36例(63.16%)转移癌细胞。统计学无显著性差别(P>0.1)。CD44s阳性见于28例(93.33%)反应性增生间皮细胞及3例(5.56%)转移癌细胞。CD44s阴性见于54例(94.44%)转移癌细胞及2例(6.67%)反应性增生间皮细胞。且2检验P<0.005,鉴别良恶性有统计学意义。结论:在胸腹水脱落细胞学中CD44s可帮助诊断转移癌;而CD44V6对于良恶性诊断价值不大。

Objective.To detect the expression and explore the clinical diagnostic significanceof adhesion moleculesrelated proteinas CD44v6, CD44s in the metastatic carcinomacells of pleural effusions and ascites by immunohistochemistry. Methods：The samples of pleural effusions and ascites were collected and made into cytoblocks. The cases selected out by HE staining and combining with their medical history of reactive proliferative mesothelial cells and metastatic carcinoma and were 30 and 57 cases respectively. Two-step immunohistochemistry technique was used to detect the expression of CD44v6 and CD44s. Results. The positive rate of CD44v6 was 23. 33%（7/30）and 36. 84% （21/57） in the proliferative mesothelial cells and metastatic carcinoma respectively. In the same time,the negative rate of CD44v6 was 76. 67% （23/30） and 63. 16%（36/57） in the proliferative mesothelial cells and metastatic carcinoma respectively. No statistical significance different between them （P〉0. 1）. CD44s was seen in the 28/30 （93. 33%）cases of proliferative mesothelial cells and 3/57 （5. 56%）cases of metastatic carcinoma respectively, The negative expression was seen in 54/57（94. 44%）cases of metastatic carcinoma and 2/30（6. 67%）cases of proliferative mesothelial cells. And the P〈0. 005 by chi - square test statistic analysis was significant value. Conclusions. It could be helpful in the differential diagnosis benign from malignant pleural effusions and ascites with CD44s negative expression, in contrast, no value was fond of CD44v6.